Sanofi snaps up new vac­cine can­di­date and de­vis­es mR­NA game plan around it — but not for what you think

Paul Hud­son has spot­light­ed vac­cines, im­munol­o­gy and der­ma­tol­ogy as some of the top R&D fo­cus­es at Sanofi. His lat­est deal brings all of them to­geth­er.

The French phar­ma gi­ant isn’t shar­ing any fi­nan­cial de­tails about the buy­out of Origimm, a low-pro­file, pri­vate Aus­tri­an biotech whose tech­nol­o­gy promis­es to iden­ti­fy anti­gens caus­ing skin dis­ease and build vac­cines against them. Their lead can­di­date tar­gets ac­ne vul­garis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER